KR102522730B1 - 디프로보심: 새로운 강력한 부류의 tlr 작용제 - Google Patents

디프로보심: 새로운 강력한 부류의 tlr 작용제 Download PDF

Info

Publication number
KR102522730B1
KR102522730B1 KR1020197002820A KR20197002820A KR102522730B1 KR 102522730 B1 KR102522730 B1 KR 102522730B1 KR 1020197002820 A KR1020197002820 A KR 1020197002820A KR 20197002820 A KR20197002820 A KR 20197002820A KR 102522730 B1 KR102522730 B1 KR 102522730B1
Authority
KR
South Korea
Prior art keywords
mmol
pyrrolidine
trans
conhch
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197002820A
Other languages
English (en)
Korean (ko)
Other versions
KR20190014133A (ko
Inventor
브루스 보이틀러
데일 엘. 보거
Original Assignee
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
더 스크립스 리서치 인스티튜트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템, 더 스크립스 리서치 인스티튜트 filed Critical 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
Publication of KR20190014133A publication Critical patent/KR20190014133A/ko
Application granted granted Critical
Publication of KR102522730B1 publication Critical patent/KR102522730B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
KR1020197002820A 2016-06-29 2017-06-29 디프로보심: 새로운 강력한 부류의 tlr 작용제 Active KR102522730B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662356314P 2016-06-29 2016-06-29
US62/356,314 2016-06-29
PCT/US2017/040028 WO2018005812A1 (en) 2016-06-29 2017-06-29 Diprovocims: a new and potent class of tlr agonists

Publications (2)

Publication Number Publication Date
KR20190014133A KR20190014133A (ko) 2019-02-11
KR102522730B1 true KR102522730B1 (ko) 2023-04-19

Family

ID=60787607

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197002820A Active KR102522730B1 (ko) 2016-06-29 2017-06-29 디프로보심: 새로운 강력한 부류의 tlr 작용제

Country Status (10)

Country Link
US (1) US11040959B2 (https=)
EP (1) EP3445758B1 (https=)
JP (1) JP6964298B2 (https=)
KR (1) KR102522730B1 (https=)
CN (1) CN109641878B (https=)
AU (1) AU2017290238B2 (https=)
BR (1) BR112018077397A2 (https=)
CA (1) CA3026178C (https=)
IL (1) IL263388B (https=)
WO (1) WO2018005812A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113164445A (zh) * 2018-08-02 2021-07-23 得克萨斯系统大学评议会 Tlr1/2激动剂地普罗考姆的佐剂作用协同增效检查点抑制性抗体以消除疾病
JP2023527792A (ja) 2020-05-27 2023-06-30 アキシャル セラピューティクス，インク． Ｔｌｒ２調節剤化合物、医薬組成物、及びそれらの使用
US20250367166A1 (en) * 2022-04-29 2025-12-04 The Scripps Research Institute Next generation diprovocims that activate the innate and adaptive immune response
US20260091126A1 (en) * 2022-09-20 2026-04-02 The Curators Of The University Of Missouri Amino acid-modified lipids for rna delivery

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050004144A1 (en) 2003-04-14 2005-01-06 Regents Of The University Of California Combined use of IMPDH inhibitors with toll-like receptor agonists
US20070161674A1 (en) 2005-11-15 2007-07-12 Scott Collibee Certain chemical entities, compositions, and methods
US20100173969A1 (en) 2001-08-08 2010-07-08 Pepys Mark B Therapeutic agent
WO2014131023A1 (en) 2013-02-25 2014-08-28 The Scripps Research Institute Neoseptins: small molecule adjuvants

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011232421B2 (en) 2010-03-23 2015-08-13 Novartis Ag Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc.
US9918959B2 (en) 2014-08-06 2018-03-20 The Board Of Regents Of The University Of Texas System TLR-independent small molecule adjuvants

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100173969A1 (en) 2001-08-08 2010-07-08 Pepys Mark B Therapeutic agent
US20050004144A1 (en) 2003-04-14 2005-01-06 Regents Of The University Of California Combined use of IMPDH inhibitors with toll-like receptor agonists
US20070161674A1 (en) 2005-11-15 2007-07-12 Scott Collibee Certain chemical entities, compositions, and methods
WO2014131023A1 (en) 2013-02-25 2014-08-28 The Scripps Research Institute Neoseptins: small molecule adjuvants

Also Published As

Publication number Publication date
CN109641878B (zh) 2021-09-14
CA3026178C (en) 2024-05-21
WO2018005812A1 (en) 2018-01-04
KR20190014133A (ko) 2019-02-11
CA3026178A1 (en) 2018-01-04
IL263388A (en) 2018-12-31
JP6964298B2 (ja) 2021-11-10
EP3445758A1 (en) 2019-02-27
US11040959B2 (en) 2021-06-22
AU2017290238B2 (en) 2021-02-18
EP3445758A4 (en) 2019-09-25
BR112018077397A2 (pt) 2019-10-01
AU2017290238A1 (en) 2018-12-13
CN109641878A (zh) 2019-04-16
JP2019519574A (ja) 2019-07-11
IL263388B (en) 2021-02-28
EP3445758B1 (en) 2020-11-04
US20200207742A1 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
CN109415387B (zh) 精氨酸酶抑制剂及其治疗应用
KR102522730B1 (ko) 디프로보심: 새로운 강력한 부류의 tlr 작용제
US20230312571A1 (en) Ring-modified proline short peptide compound and use thereof
US20150018340A1 (en) Pipecolate-diketoamides for treatment of psychiatric disorders
WO2024183821A1 (zh) 可离子化脂质分子及其制备方法和应用
TW201217332A (en) Caspase inhibitors and uses thereof
JP6643484B2 (ja) ７−オキソ−６−（スルホオキシ）−１，６−ジアザビシクロ［３．２．１］オクタン−２−カルボキサミド含有化合物および細菌感染症の治療におけるそれらの使用
CA3196221A1 (en) Conjugated tlr7 and nod2 agonists
TW442469B (en) Fibrinogen receptor antagonists having substituted β-amino acid residues and pharmaceutical compositions comprising the same
IL324431A (en) Anti-hiv compounds
JPH024748A (ja) 薬理作用を有するペプチド類
CN120603813A (zh) 2-氨基-n-(4-氨基-3,4-二氧代-1-(2-氧代吡咯烷-3-基)丁-2-基)苯甲酰胺衍生物作为蛋白酶抑制剂用于治疗或预防冠状病毒感染
US20250367166A1 (en) Next generation diprovocims that activate the innate and adaptive immune response
FR2622195A1 (fr) Nouveaux isopolypeptides, procede pour leur preparation et medicaments les contenant
HK40107352A (zh) 用於局部递送治疗剂的药物递送系统以及其用途
HK40060177A (en) Derivative compound introducing biphenyl group into novel aminoalkanoic acid and antifungal pharmaceutical composition comprising same
HU208156B (en) Process for producing /n-(gamma-glutamyl)-glycyl/-alanine derivatives and pharmaceutical compositions comprising same
HK40018376B (en) Hiv inhibitor compounds

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601